By Fineline Cube 
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving dual clinical trial approvals from the National Medical Products Administration (NMPA) for its investigational therapies HS-20122 and HS-20108. This milestone underscores the company’s commitment to expanding its oncology pipeline and advancing next-generation cancer treatments.
HS-20122: Antibody-Drug Conjugate (ADC)
HS-20122 is an antibody-drug conjugate (ADC) designed to target advanced solid tumors, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and colorectal cancer (CRC). The ADC mechanism delivers cytotoxic agents directly to cancer cells, minimizing systemic exposure and enhancing therapeutic efficacy.
HS-20108: Novel Therapy for Small Cell Lung Cancer
HS-20108 is a novel therapeutic candidate in development for small cell lung cancer (SCLC), neuroendocrine tumors, and other advanced solid malignancies. This therapy represents Hansoh’s innovation in addressing high unmet medical needs in aggressive cancer types.
Clinical Trial Objectives
The clinical trials for both HS-20122 and HS-20108 will evaluate their safety, tolerability, pharmacokinetics, and preliminary efficacy. These studies are designed to provide robust data supporting their potential as new treatment options for patients with advanced cancers.
Market Potential
Hansoh’s expanding oncology portfolio positions the company to compete effectively in the global cancer therapy market. The approvals highlight Hansoh’s strategic focus on developing innovative solutions for cancer patients, leveraging cutting-edge technology to address significant unmet medical needs.-Fineline Info & Tech